MANCHESTER, England--(BUSINESS WIRE)--Synexus is understandably proud of its clinical trials recruitment model and the continued growth its business has enjoyed during the past few years, what it had not anticipated, was the demand for its services from sponsors whose trials were in urgent need of rescuing, and in particular those sponsoring vaccine trials. Dr Christophe Berthoux, Synexus CEO acknowledges that the Synexus model is particularly suited to recruiting large number of patients for late phase trials, but says the company had not foreseen the level of demand for rescuing failing trials: “We have long since established ourselves as premium providers when it comes to delivering significant numbers of patients quickly, with our 26 Dedicated Research Centres and 450,000 strong patient database. This is a given, but the level of demand for our centres to come to the aid of failing vaccine studies, has been a surprise.”
